<DOC>
	<DOCNO>NCT00152425</DOCNO>
	<brief_summary>A 26 week maintenance study CDP870 Crohn 's disease</brief_summary>
	<brief_title>Study Test Effect CDP870 Treatment Crohn 's Disease Over 26 Weeks , Comparing CDP870 Dummy Drug ( Placebo ) , Following 3 Doses Active Drug ( CDP870 ) .</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Definitive diagnosis Crohn 's disease confirm ( least 3 month prior study entry ) either radiological , endoscopic histological evidence , affect terminal ileum ( L1 ) , colon ( L2 ) ileocolon ( L3 ) * . * Vienna Classification ( 1998 ) Active Crohn 's disease ( ≥ 220 ≤ 450 ) score 7 day prior first dose study drug . Patients age 18 year screen . Crohn 's Disease Related Fistula abscess present screening . Stricturing type disease symptom sign noninflammatory mechanical obstruction bowel perforation last 3 month . Short bowel syndrome . Functional colostomy ileostomy ( note : patient temporary stoma past , reverse , eligible enter study ) . Positive stool laboratory result enteric pathogen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Crohn 's disease , CDP870 , CDAI , clinical response , remission , Certolizumab Pegol , Cimzia</keyword>
</DOC>